The neoantigen landscape is shifting from broad validation to structural precision and commercial scaling.
Merck and Moderna are advancing individualized mRNA therapies for clinical deployment, while new computational resources like SPLISOFORMS aim to resolve the structural validity of splice-variant neoepitopes.Southwest VoicesnewsbioRxiv
The SPLISOFORMS knowledge base integrates AlphaFold 3 predictions with long-read transcriptomes to map the structural consequences of alternative splicing in cancer. By annotating 124,687 isoform structures for neoepitope presentation and druggability, it offers a critical tool for validating whether splice variants yield viable neoantigens beyond sequence-level annotations.
Long-term follow-up data from IDH1 vaccination trials provides critical durability signals for shared neoantigen strategies. This evidence supports the viability of targeting common mutations, offering a potential complement to personalized approaches in specific molecular subsets.
Merck and Moderna are advancing their individualized neoantigen therapy (INT) platform, leveraging mRNA to train immune systems against patient-specific tumor fingerprints. This commercial partnership highlights the industry's pivot toward 'one medicine for one patient' models, aiming to address genetic uniqueness in cancer care.
Relevant work from earlier we're still surfacing — not today's news.